abstract |
The present invention relates to steroid hormone dependent diseases useful in therapy, particularly steroids that require inhibition of 17β-hydroxysteroid dehydrogenase (17β-HSD), such as 17β-HSD type 1, type 2 or type 3 enzyme. It relates to novel estratriene-triazoles of general formula (I) for use in the treatment and / or prevention of hormone-dependent diseases or disorders. |